Tag Archives: Private Credit

Bridgepoint prices reset of Bridgepoint CLO V

Bridgepoint prices reset of Bridgepoint CLO V

Bridgepoint has today announced the successful pricing of the reset of Bridgepoint CLO V.

The transaction extends the investment period to 2030 and lowers the cost of capital of the original 2023 deal.

Bridgepoint’s third CLO transaction of 2025, the reset saw strong demand throughout the full capital stack, evidencing the market’s continued appetite for Bridgepoint’s disciplined approach to investment and credit selection.

Commenting on the transaction, John Murphy, Partner and Bridgepoint’s Head of Syndicated Debt, said:

“We’re pleased to have seen such strong continued interest from our broader investor base with the reset of Bridgepoint CLO V. By combining a long-term reinvestment horizon with a flexible, high-conviction approach to portfolio management, we’ve shown our platform can adapt to changing markets and unlock consistent value. This robust investor demand speaks to the trust placed in our differentiated approach.”

With more than €14 billion of assets under management in corporate credit across the risk/reward spectrum, Bridgepoint Credit is one of Europe’s most experienced credit managers. It focuses on three complementary investment strategies: Direct Lending, Credit Opportunities and Syndicated Debt.

Bridgepoint Group is one of the world’s leading quoted private asset growth investors, specialising in private equity, infrastructure and private credit.

With over $86 billion of assets under management and a strong local presence in Europe, North America and Asia, we combine global scale with local market insight and sector expertise, consistently delivering strong returns through cycles.

Bridgepoint Advisers Limited, a subsidiary of Bridgepoint Group plc, is authorised and regulated by the Financial Conduct Authority.

Categories: News

Tags:

Coller Capital expands global reach through strategic partnership with Allfunds

Coller Capital

  • The partnership will distribute CollerEquity and CollerCredit to accredited private investors, wealth managers and family offices.
  • It will provide global individual investors with access to institutional-quality private equity and credit secondaries, enabling them to benefit from the liquidity and resilience that private markets secondaries afford.

London 6th June 2025 – Coller Capital, the world’s largest dedicated private market secondaries manager, has today announced a global distribution partnership with Allfunds, the leading end-to-end WealthTech partner for the wealth and asset management industries with more than $1.5 trillion assets under administration across Mutual Funds, Alternative Assets and ETFs. This global partnership will see Coller Private Equity Secondaries (CollerEquity) and Coller Private Credit Secondaries (CollerCredit) made available to the 19,000 accredited private investors, wealth managers and family offices on the Allfunds platform.

CollerEquity launched in July 2024. The Fund’s portfolio consists of institutional quality private equity assets diversified by GP-manager, and fund vintage as well as by geography and sector. Alongside diversification, the Fund seeks to deliver a combination of absolute and risk-adjusted returns and the opportunity for more liquidity than traditional private equity funds.

CollerCredit launched in October 2024. The portfolio is diversified across vintages, managers, industrial sectors and geography. While its core focus is on senior direct lending opportunities, it has the flexibility to invest across other credit strategies opportunistically if risk-adjusted returns and liquidity profiles are deemed to be appropriate.

Both CollerEquity and CollerCredit and its regional feeder funds are available to professional and qualified investors in a range of global jurisdictions, including across Europe, the Middle East, Canada, Asia, and Australia in compliance with local law. The Funds’ clients are supported by Coller’s Private Wealth Secondaries Solutions (PWSS) team, which now consists of 50 dedicated professionals supported by the wider Coller platform. Both Funds provide investors with access to Coller Capital’s 35 years of secondaries investment expertise and its global platform. They offer monthly subscriptions and quarterly redemptions, and can be accessed with USD 50,000 minimum commitment.

Jake Elmhirst, Partner, Head of Private Wealth Secondaries Solutions and Deputy Head of Capital Formation at Coller Capital, said: “Coller Capital has a long-standing reputation for innovation in private markets secondaries, and that spirit drives our wealth strategy. The strategic investment approach underpinning CollerEquity and CollerCredit provides investors with diversified, risk-adjusted returns, as well as portfolio resilience in times of wider market dislocation. This partnership with Allfunds widens the spectrum of investors who have access to these benefits, and we look forward to working with their team.”

Boris Maeder, Managing Director and Head of International Private Wealth Distribution at Coller Capital, said: “Through this global partnership with Allfunds, we are making CollerEquity and CollerCredit more accessible to a wider range of investors. It represents a meaningful step in broadening access to private equity and private credit secondaries, which are powerful tools for portfolio diversification, liquidity and resilience – including in times of wider market uncertainty.”

Borja Largo, Chief Fund Groups Officer for Allfunds said: “This partnership with Coller Capital unlocks exciting new access to private market secondaries for our clients, strengthening Allfunds’ position as the largest and most comprehensive marketplace for wealth and asset management solutions. We remain dedicated to continuously enhancing our private markets offering to empower our clients and help them grow.”

Coller Capital has offices in London, New York, Hong Kong, Beijing, Seoul, Luxembourg, Zurich, Melbourne, Montreal and Singapore. The firm manages $40 billion in secondaries across private equity, private credit, and other private market vehicles and has 35 years of experience in the secondary private capital market.

About Coller Private Equity Secondaries – (“CollerEquity”) and Coller Private Credit Secondaries (“CollerCredit”)

THIS IS A MARKETING COMMUNICATION IN RESPECT OF THE FUND. PLEASE REFER TO THE PROSPECTUS, KEY INFORMATION DOCUMENT, GOVERNING AND OTHER RELEVANT DOCUMENTS FOR THE FUND BEFORE MAKING ANY INVESTMENT DECISION

Potential investors should be aware that an investment in the CollerEquity and/or CollerCredit (including any related overflow, co-investment, or other vehicles, the “Funds”) is speculative and involves a high degree of risk, and is suitable only for those investors who have the financial sophistication and expertise to evaluate the merits and risks of an investment in the Fund(s) and for which such Fund(s) do(es) not represent a complete investment program. An investment should only be considered by persons who can afford a loss of their entire investment. The following is a summary of only certain considerations and is qualified in its entirety by the more detailed risks and conflicts in the CollerEquity and CollerCredit prospectuses. Investors are urged to consult with their own tax and legal advisors about the implications of investing in the Fund. Fees and expenses can be expected to reduce the overall return of the Fund.

Investors should carefully consider the investment objectives, risks, charges and expenses of CollerEquity and/or CollerCredit. This and other important information about the Funds are contained in the relevant prospectus. Please read the prospectus(es) carefully before investing. The CollerEquity Prospectus can be found here. The CollerCredit Prospectus can be found here.

General Risks. Coller Capital cannot ensure that it can choose, make and realize investments in any particular investment fund or portfolio of investment funds. There is no assurance CollerEquity and/or CollerCredit will be able to generate returns for the investors or that returns will be commensurate with the risks of investing in the type of companies and investments in which CollerEquity and/or CollerCredit may indirectly invest. An investment in CollerEquity and/or CollerCredit should only be considered by persons who can afford a loss of their entire investment. There can be no assurance that CollerEquity and/or CollerCredit’s investment objectives will be achieved or that investors will receive a return on their capital. Any investment in CollerEquity and/or CollerCredit entails risks, including but not limited to the risk of losing all or part of the amount invested. There can be no assurance that CollerEquity and/or CollerCredit will be able to implement its investment strategy or achieve its investment objectives.

Specific risks: Lack of Operating History. Diversification. Competition. Limited Current Return. Illiquidity; Transfer Restrictions. Leverage. Exchange Rate Fluctuations.

Performance is generally subject to taxation which depends on the particular situation of each investor and which may change in the future. The operating or chosen currency of an investor may also impact upon returns that may be realised by that investor.

Capital is at risk and investors may not receive back the amount they invest. The strategy of the Funds does not guarantee a profit or ensure protection against losses. There can be no assurance that the Funds will achieve their objectives or avoid significant losses.

Mentions
Black and white formal headshot of Jake Elmhirst.
Jake Elmhirst

Partner, Head of Private Wealth Secondaries Solutions and Deputy Head of Capital Formation
Black and white formal headshot of Boris Maeder.
Boris Maeder

Managing Director and Head of International Private Wealth Distribution
Press contact
Edelman Smithfield

coller@edelmansmithfield.com+44 (0)7980 684 247

News
6 Ju

Categories: News

Tags:

Antares Closes $1.2 Billion Private Credit Continuation Vehicle Led by Ares Management

Antares
CHICAGO & NEW YORK–(BUSINESS WIRE)– Antares Capital and Ares Management Corporation (“Ares”) (NYSE: ARES) today announced the closing of Antares’ first continuation vehicle with over $1.2 billion in commitments. The transaction was led by Ares Credit Secondaries funds, along with a commitment from Antares.

The continuation vehicle was established to purchase assets and limited partner interests from two comingled private credit funds comprising over 100 underlying first lien, floating rate loans originated and managed by Antares. The vehicle provided existing investors with an attractive liquidity option while offering new investors exposure to quality Antares-originated private credit assets.

“This transaction underscores our strong, long-standing partnership with Ares and our shared commitment to providing quality private credit opportunities,” said Vivek Mathew, president of Antares Capital Advisers. “It also marks an important step in expanding the Antares platform and delivering new liquidity solutions to our investors.”

“We are pleased to welcome Ares as a lead investor and believe the successful close of our first continuation vehicle in today’s dynamic market highlights the quality of the Antares portfolio and the power of our origination and underwriting capabilities,” said Ben Chapin, Head of Liquidity Solutions at Antares Capital. “We are committed to structuring differentiated liquidity options tailored to both LPs and GPs, leveraging our extensive private credit experience, deep relationships and focus on credit discipline.”

“Building upon our multidecade relationship with Antares, we are proud to lead this transaction, which represents Ares’ largest credit secondary investment to date,” said Dave Schwartz, Head of Credit Secondaries, Ares. “This investment underscores our team’s differentiated experience in private credit and secondaries and our ability to deploy scaled capital. We look forward to leveraging our global relationships with leading private credit managers to deliver creative liquidity solutions that meet the needs of investors.”

Evercore served as exclusive financial advisor on the transaction.

About Antares Capital
Founded in 1996, Antares has been a leader in private credit for nearly three decades. Today with approximately $80 billion* of capital under management and administration as of December 31, 2024, Antares is an experienced and cycle-tested alternative credit manager. With one of the most seasoned teams in the industry, Antares is focused on delivering attractive risk-adjusted returns for investors and creating long term value for all of its partners. The firm maintains offices in Atlanta, Chicago, Los Angeles, New York, Toronto and London. Visit Antares at www.antares.com or follow the company on LinkedIn at https://www.linkedin.com/company/antares-capital-lp.

Antares Capital is a subsidiary of Antares Holdings LP, (collectively, “Antares”). Antares Capital London Limited is an appointed representative of Langham Hall Fund Management LLP, an entity which is authorized and regulated by the Financial Conduct Authority of the UK.

*As of December 31, 2024, all figures are estimates and subject to change upon finalization.

About Ares Management Corporation
Ares Management Corporation (NYSE: ARES) is a leading global alternative investment manager offering clients complementary primary and secondary investment solutions across the credit, real estate, private equity and infrastructure asset classes. We seek to provide flexible capital to support businesses and create value for our stakeholders and within our communities. By collaborating across our investment groups, we aim to generate consistent and attractive investment returns throughout market cycles. As of March 31, 2025, Ares Management Corporation’s global platform had approximately $546 billion of assets under management, with operations across North America, South America, Europe, Asia Pacific and the Middle East. For more information, please visit www.aresmgmt.com.

Antares
Allison Perkins
allison.perkins@antares.com

Ares
Jacob Silber | Lauren Sullivan
media@aresmgmt.com

Source: Antares Capital

Back to Media

Categories: News

Tags:

KKR Provides $600 Million Financing to Indian Conglomerate Manipal Group

KKR

Transaction marks KKR’s latest and largest credit investment in India

MUMBAI, India–(BUSINESS WIRE)– KKR, a leading global investment firm, and Manipal Education and Medical Group (“MEMG” or “Manipal Group”), a major diversified conglomerate in India, today announced a $600-million financing arranged by KKR Capital Markets and anchored by KKR’s private credit and insurance platforms to the Manipal Group. The investment will enable the Manipal Group to accelerate its corporate expansion and growth objectives by providing flexible, structured capital matched to its long-term strategic needs.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250601919977/en/

The Manipal Group is a leading conglomerate in India with various institutions and major businesses across the healthcare, education, and health insurance sectors, including Manipal Health Enterprises, one of India’s top multispecialty hospitals chains in India.

KKR’s Asia Pacific Credit platform seeks to provide, among other private credit strategies, bespoke solutions to high-quality companies, entrepreneurs, promoters and sponsors that harness the strength of KKR’s private markets investment capabilities and its expertise as one of the largest alternative credit managers globally.

Gaurav Trehan, Co-Head of KKR Asia Pacific and Head of Asia Private Equity, KKR said, “We are pleased to deepen our relationship with the Manipal Group and Dr Ranjan Pai, who have established one of India’s pre-eminent and homegrown businesses, as they continue to deliver on their long-term vision. The Manipal Group has built a strong reputation over the decades as one of India’s healthcare and education leaders, and we look forward to supporting and contributing to their continued success.”

Dr. Ranjan Pai, Chairman of Manipal Education and Medical Group, said, “We are proud to welcome KKR as a strategic partner as we continue to build on Manipal’s legacy in healthcare and education. KKR’s longstanding India focus and flexible capital approach, as well as alignment with our long-term vision, present a strong fit for us.”

Diane Raposio, Partner and Head of Asia Credit and Markets at KKR, added, “This transaction underscores the strength of our global credit platform and our ability to provide strategic, scaled capital solutions to leading businesses. India is a priority market for our credit strategy, and we look to build on this momentum to be a partner of choice to more high-quality companies like Manipal on their growth ambitions.”

KKR is making its investment from its Asia Pacific Credit strategy and insurance platform. Since 2019, KKR has committed more than $8 billion across around 60 credit investments under its Asia Pacific Credit strategy, accounting for a total transaction volume of more than $21 billion.

Additional details of the transaction are not disclosed.

About KKR

KKR is a leading global investment firm that offers alternative asset management as well as capital markets and insurance solutions. KKR aims to generate attractive investment returns by following a patient and disciplined investment approach, employing world-class people, and supporting growth in its portfolio companies and communities. KKR sponsors investment funds that invest in private equity, credit and real assets and has strategic partners that manage hedge funds. KKR’s insurance subsidiaries offer retirement, life and reinsurance products under the management of Global Atlantic Financial Group. References to KKR’s investments may include the activities of its sponsored funds and insurance subsidiaries. For additional information about KKR & Co. Inc. (NYSE: KKR), please visit KKR’s website at www.kkr.com. For additional information about Global Atlantic Financial Group, please visit Global Atlantic Financial Group’s website at www.globalatlantic.com.

About Manipal Education and Medical Group (MEMG)

Founded in 1953 by Padma Shri Dr TMA Pai, MEMG has evolved into a diversified conglomerate, with a strong presence in healthcare, education and health insurance in India and globally. MEMG’s operations touch the lives of over 20 million people annually with Manipal Hospitals scaling up to become the largest tertiary network in India. MEMG’s flagship University, Manipal Academy of Higher Education has been recognized as an Institute of Eminence by the Government of India. Claypond Capital, the family office of Dr. Pai and the investing arm of MEMG has been one of the more prolific investing family offices in India in the last 18 months. Their marquee investments include Aakash, BPL Medical, BlueStone, Easy Home Finance, First Cry, Finnable, InCred Finance, NSE, Panacea Medical, PharmEasy, Purpple, Recykal, SSI Innovations and Zepto.

Media Contacts

For KKR Asia Pacific
Wei Jun Ong
+65 6922 5813
WeiJun.Ong@kkr.com

For Manipal Group
Shyam Powar
+91 98804 75000
Shyam.Powar@claypondcapital.com

Source: KKR

 

Download PDF

Categories: News

Tags:

Axsome Therapeutics Enters $570 Million Term Loan and Revolving Credit Facility with Blackstone

Blackstone

Previous term loan facility retired

NEW YORK – May 13, 2025 – Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it has entered into a $570 million term loan and revolving credit facility with funds managed by Blackstone Life Sciences and Blackstone Credit & Insurance (“Blackstone”). Concurrent with this new facility, Axsome has retired its previous term loan with Hercules Capital. The improved financial terms and expected use of the new facility are expected to result in a significant reduction in interest expense.

“The new agreement with Blackstone simultaneously expands our total available credit facility by more than $200 million, and significantly reduces our cost of capital,” said Herriot Tabuteau, MD, Chief Executive Officer of Axsome Therapeutics. “We are pleased to partner with the Blackstone team given their differentiated expertise in the life sciences industry. The improved terms of the new facility underscore our commitment to accelerating time to profitability and enhancing shareholder value, while advancing our mission to improve the lives of patients living with serious CNS disorders.”

“Blackstone is proud to partner with Axsome at a time of growth and expanding commercial opportunity,” said Craig Shepherd and Kiran Reddy, MD, Senior Managing Directors with Blackstone Life Sciences. “This investment is designed to reinforce the company’s operational and financial agility to support its next phase of growth, and it is a testament to Blackstone’s ability to deliver customized and flexible financing solutions to help leading biopharma companies achieve their strategic objectives.”

Brad Colman, Global Head of Healthcare with Blackstone Credit & Insurance, added, “Axsome’s proven commercial success, innovative pipeline, and strong leadership team make it an ideal partner as we continue to invest in transformative therapies to help patients. This transaction exemplifies how we can provide scaled credit solutions to world-class life sciences companies.”

The new $570 million facility consists of a $500 million term loan facility and a $70 million revolving credit facility. Upon closing of the agreement, the Company drew down a total of $120 million from the term loan facility which was used to retire the previous term loan with Hercules Capital. Under the terms of the new term loan facility, an additional $250 million may be drawn at the Company’s option, with an additional $200 million available subject to the approval of Blackstone. The facility bears interest at a calculated SOFR variable rate plus 4.75% for the term loan, and SOFR variable rate plus 4.0% for the revolving credit facility. The facility matures in May 2030 and has an interest-only payment period of 60 months. Concurrent with the closing of the agreement, Blackstone purchased $15 million of Axsome common stock at the 30-day volume weighted average price per share equal to $107.14.

Additional details regarding the financing agreement are available in the Company’s Form 8-K to be filed with the Securities and Exchange Commission.

About Axsome Therapeutics
Axsome Therapeutics is a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) conditions. We deliver scientific breakthroughs by identifying critical gaps in care and develop differentiated products with a focus on novel mechanisms of action that enable meaningful advancements in patient outcomes. Our industry-leading neuroscience portfolio includes FDA-approved treatments for major depressive disorder, excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea, and migraine, and multiple late-stage development programs addressing a broad range of serious neurological and psychiatric conditions that impact over 150 million people in the United States. Together, we are on a mission to solve some of the brain’s biggest problems so patients and their loved ones can flourish. For more information, please visit us at www.axsome.com and follow us on LinkedIn and X.

About Blackstone Life Sciences
Blackstone Life Sciences (BXLS) is an industry-leading private investment platform with capabilities to invest across the life cycle of companies and products within the key life science sectors. By combining scale investments and hands-on operational leadership, BXLS helps bring to market promising new medicines and medical technologies that improve patients’ lives and currently has $12 billion in assets under management.

About Blackstone Credit & Insurance
Blackstone Credit & Insurance (“BXCI”) is one of the world’s leading credit investors. Our investments span the credit markets, including private investment grade, asset-based lending, public investment grade and high yield, sustainable resources, infrastructure debt, collateralized loan obligations, direct lending and opportunistic credit. We seek to generate attractive risk-adjusted returns for institutional and individual investors by offering companies capital needed to strengthen and grow their businesses. BXCI is also a leading provider of investment management services for insurers, helping those companies better deliver for policyholders through our world-class capabilities in investment grade private credit.

Forward Looking Statements
Certain matters discussed in this press release are “forward-looking statements”. The Company may, in some cases, use terms such as “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. In particular, the Company’s statements regarding trends and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the commercial success of the Company’s SUNOSI®, AUVELITY®, and SYMBRAVO® products and the success of the Company’s efforts to obtain any additional indication(s) with respect to solriamfetol and/or AXS-05; the Company’s ability to maintain and expand payer coverage; the success, timing and cost of the Company’s ongoing clinical trials and anticipated clinical trials for the Company’s current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including the Company’s ability to fully fund the Company’s disclosed clinical trials, which assumes no material changes to the Company’s currently projected revenues or expenses), futility analyses and receipt of interim results, which are not necessarily indicative of the final results of the Company’s ongoing clinical trials, and/or data readouts, and the number or type of studies or nature of results necessary to support the filing of a new drug application (“NDA”) for any of the Company’s current product candidates; the Company’s ability to fund additional clinical trials to continue the advancement of the Company’s product candidates; the timing of and the Company’s ability to obtain and maintain U.S. Food and Drug Administration (“FDA”) or other regulatory authority approval of, or other action with respect to, the Company’s product candidates, including statements regarding the timing of any NDA submission; the Company’s ability to successfully defend its intellectual property or obtain the necessary licenses at a cost acceptable to the Company, if at all; the successful implementation of the Company’s research and development programs and collaborations; the success of the Company’s license agreements; the acceptance by the market of the Company’s products and product candidates, if approved; the Company’s anticipated capital requirements, including the amount of capital required for the commercialization of SUNOSI, AUVELITY, and SYMBRAVO and for the Company’s commercial launch of its other product candidates, if approved, and the potential impact on the Company’s anticipated cash runway; the Company’s ability to convert sales to recognized revenue and maintain a favorable gross to net sales; unforeseen circumstances or other disruptions to normal business operations arising from or related to domestic political climate, geo-political conflicts or a global pandemic and other factors, including general economic conditions and regulatory developments, not within the Company’s control. The factors discussed herein could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

Axsome Contacts:

Investors:
Mark Jacobson
Chief Operating Officer
(212) 332-3243
mjacobson@axsome.com

Media:
Darren Opland
Director, Corporate Communications
(929) 837-1065
dopland@axsome.com

Blackstone:
David Vitek
(212) 583-5291
David.Vitek@blackstone.com

Categories: News

Tags:

Blackstone Launches BMACX – Blackstone Private Multi-Asset Credit and Income Fund

Blackstone

NEW YORK – May 1, 2025 – Blackstone (NYSE: BX) today announced the launch of Blackstone Private Multi-Asset Credit and Income Fund (BMACX), the firm’s first private multi-asset credit interval fund (the “Fund”). Investors can now access BMACX through select registered investment advisers.

BMACX aims to provide individual investors with a one-stop, private multi-asset credit solution designed to access strategies across Blackstone’s leading $465 billion credit platform. The Fund offers ticker execution with daily subscriptions, quarterly liquidity, and low investment minimums with capital invested immediately.

“We believe BMACX can be a powerful core portfolio building block to tap the expanding credit markets,” said Heather von Zuben, Chief Executive Officer of BMACX. “It brings the full breadth of Blackstone’s credit platform to individuals in what we see as an investor friendly structure.”

“We will aim to deliver high quality, diversified income with lower volatility than traditional fixed income products by investing across a diverse range of compelling credit assets,” said Dan Oneglia, Chief Investment Officer of BMACX. “We believe this multi-strategy approach positions investors to take advantage of attractive relative value, particularly in dynamic market environments.”

BMACX will invest across a diverse range of credit assets, including private corporate credit, asset based and real estate credit, structured credit, and liquid credit, seeking to deliver attractive and stable income through a monthly distribution while managing risk.

BMACX builds on Blackstone’s leadership position delivering private credit solutions to individual investors, with dedicated vehicles focused on direct lending available since 2018.

Blackstone announced that BMACX was declared effective by the U.S. Securities and Exchange Commission in March. More information is available at www.bmacx.com.

About Blackstone Credit & Insurance
Blackstone Credit & Insurance (“BXCI”) is one of the world’s leading credit investors. Our investments span the credit markets, including private investment grade, asset based lending, public investment grade and high yield, sustainable resources, infrastructure debt, collateralized loan obligations, direct lending and opportunistic credit. We seek to generate attractive risk-adjusted returns for institutional and individual investors by offering companies capital needed to strengthen and grow their businesses. BXCI is also a leading provider of investment management services for insurers, helping those companies better deliver for policyholders through our world-class capabilities in investment grade private credit.

About Blackstone Private Wealth   
Blackstone Private Wealth was established to answer the growing demand for Blackstone products from high-net worth investors. Partnering with many of the world’s largest private banks and wealth management firms as well as family offices, Blackstone’s Private Wealth team packages and delivers the full breadth of Blackstone’s alternative product capability to these firms and their clients and provides ongoing product and advisor support, as well as education and training around alternatives.

Forward-Looking Statements
Certain information contained in this communication constitutes “forward looking statements” within the meaning of the federal securities laws. These forward-looking statements can be identified by the use of forward-looking terminology, such as “outlook,” “indicator,” “believes,” “expects,” “potential,“ “continues,” “may,” “can,” “will,“ “could,” “should,” “seeks,” “approximately,” “predicts,“ “intends,” “plans,” “estimates,” “anticipates”, “confident,” “conviction,“ “identified” or the negative versions of these words or other comparable words thereof.

These may include financial estimates and their underlying assumptions, statements about plans, objectives and expectations with respect to future operations, statements regarding future performance, statements regarding economic and market trends and statements regarding identified but not yet closed investments. Such forward-looking statements are inherently subject to various risks and uncertainties. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in such statements. BMACX believes these factors also include but are not limited to those described under the section entitled “Risk Factors” in its prospectus, and any such updated factors included in its periodic filings with the Securities and Exchange Commission (the “SEC”), which are accessible on the SEC’s website at www.sec.gov. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in this document (or BMACX’s prospectus and other filings). Except as otherwise required by federal securities laws, BMACX undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.

This press release must be read in conjunction with the BMACX prospectus in order to fully understand all the implications and risks of an investment in BMACX. This press release is neither an offer to sell nor a solicitation of an offer to buy securities. An offering is made only by the prospectus, which should be read carefully before investing and is available at www.bmacx.com.  Before investing you should carefully consider BMACX’s investment objectives, risks, charges and expenses.  This and other information is in BMACX’s prospectus.

An investment in the Fund involves a high degree of risk. There is no assurance that the Fund will achieve its investment objectives.  An investment in the Fund is suitable only for investors who can bear the risks associated with limited liquidity.  Shares of the Fund are not listed on any securities exchange and the Fund does not expect any secondary market will develop for the shares. The Fund intends to utilize leverage and may utilize leverage to the maximum extent permitted by law for investment and other general corporate purposes, which will magnify the potential for loss on amounts invested in the Fund. Please see the prospectus for details of these and other risks.

The Fund is distributed by Blackstone Securities Partners L.P. BMACX is a newly formed investment company with no operating or performance history that shareholders can use to evaluate the Fund.

Contact
Thomas Clements
Thomas.Clements@blackstone.com
(646) 482-6088

Categories: News

Tags:

CVC Credit prices $475m Apidos LIII

CVC Capital Partners

CVC Credit, the $47bn global credit management business of CVC, is pleased to announce that it has successfully priced Apidos LIII (53), a new $475m Collateralized Loan Obligation (“CLO”). Societe Generale served as lead arranger for CVC Credit’s second US CLO New Issue pricing in 2025.

This is the third new CLO priced globally by CVC Credit in 2025, which combined have an aggregate value of c.$1.4bn (c.€1.3bn). Apidos LIII has a five-year reinvestment period and two-year non-call period, backed by a diversified portfolio of senior secured assets.

Cary Ho, Partner and Global Head of CLO origination at CVC Credit, said: “Apidos LIII was very well received from our global investors during very challenging market conditions, which reflects CVC’s proven track record, and the strength of our relationships with global investors across the capital stack.  We are happy with the structure and the quality of assets we have been able to purchase during the early stages of this deal.”

Quotes

We believe the volatility over the last couple of months has and will continue to create attractive investment options for our investors and we will strive to capitalize on these opportunities.

Kevin O’MearaPartner and Global Co-Head of Performing Credit at CVC Credit

Kevin O’Meara, Partner and Global Co-Head of Performing Credit at CVC Credit, added: “Our team’s activity has remained robust over the past four months, even against the backdrop of increased volatility across financial markets. Since the inception of our business in 2005, our growing and loyal investor base has entrusted us with delivering stable and consistent performance throughout cycles.  We believe the volatility over the last couple of months has and will continue to create attractive investment options for our investors and we will strive to capitalize on these opportunities.”

Categories: News

Tags:

Carlyle provides financing package to Suntera Global

Carlyle

St. Helier, Jersey, 22 April 2025 – Global investment firm Carlyle (NASDAQ: CG) today announced that its Global Credit platform has provided a financing package to Suntera Global (“Suntera”), an independent global provider of bespoke fund, corporate and private wealth services.

Founded in 1980, Suntera provides a full suite of professional services to corporates, fund managers, and private clients (including their family offices). Through a comprehensive range of administration, accounting and governance services, Suntera helps its long-standing international base of clients navigate the complex and evolving demands that come with managing wealth and cross-border capital, focusing on reducing clients’ compliance, regulatory, and reporting risks. The company employs more than 500 specialists in offices across Europe, Asia and North America.

This financing package will strengthen the company’s financial foundation by refinancing its existing indebtedness and provide additional capital to support Suntera through organic growth initiatives and strategic acquisitions.

Nicola Falcinelli, Deputy Head of European Private Credit at Carlyle, said: “We are delighted to support Suntera’s continued growth story through this strategic financing. We believe Suntera is strongly positioned to meet growing and resilient demand for specialized professional services, particularly within the context of a rapidly evolving and complex regulatory landscape. This transaction underscores Carlyle’s established strategy of supporting high-quality businesses with flexible capital solutions.”

David Hudson, CEO of Suntera, said: “Since the Management Buy Out in 2019, Suntera has built on its core heritage, grown its international footprint through strong organic and inorganic growth, and established a reputation for its highly specialized capability and diversified proposition which spans multiple strategies, geographies and service lines. We are grateful for the support of Carlyle, which enables Suntera to continue to pursue its growth ambitions through its first-class customer offering, and the continuation of its highly successful consolidation strategy.”

Carlyle’s Global Credit platform manages $192 billion in assets under management, as of December 31, 2024. It regularly pursues investments in privately negotiated capital solutions partnering with high-quality sponsors and leading family or entrepreneur-owned companies. The Suntera transaction follows an active last few months for Carlyle’s European credit platform, recently announcing investments including Argon, Sanoptis, and Bianalisi.

 

—

About Carlyle 

Carlyle (NASDAQ: CG) is a global investment firm with deep industry expertise that deploys private capital across three business segments: Global Private Equity, Global Credit, and Global Investment Solutions. With $441 billion of assets under management as of December 31, 2024, Carlyle’s purpose is to invest wisely and create value on behalf of its investors, portfolio companies, and the communities in which we live and invest. Carlyle employs more than 2,300 people in 29 offices across four continents. Further information is available at www.carlyle.com. Follow Carlyle on X @OneCarlyle and LinkedIn at The Carlyle Group.

 

About Suntera Global

Suntera Global is a multi-jurisdictional provider of fund, corporate and private wealth services. We believe in empowering responsible ambition through the professional delivery of fund, company and trust administration as well as outsourced compliance, accounting and tax services. Suntera employs over 500 specialists supporting a global client base from offices in the Bahamas, the Cayman Islands, Hong Kong, the Isle of Man, Jersey, Guernsey, Luxembourg, the UK and the USA.

For more information visit suntera.com

 

Media contacts:

Carlyle:

Charlie Bristow

Tel: +44 (0) 7384 513568

Email: charlie.bristow@carlyle.com

 

Suntera Global: 

Cara Pyper
cara.pyper@suntera.com

Categories: News

Tags:

Coller Capital partners with Barings Portfolio Finance and Ares on $2.4 billion structured funding vehicle to invest in private market secondaries

Coller Capital

London, April 17, 2025 – Coller Capital, the world’s largest dedicated private market secondaries manager, today announces that it has partnered with Barings Portfolio Finance and Ares Management Alternative Credit funds (“Ares”) to raise a $2.4 billion structured funding vehicle for Coller funds to invest in private market secondaries.

This innovative solution marks the largest-ever structured funding vehicle of its kind in the secondary market to invest in both private equity and private credit secondaries. This transaction was led by Coller’s Structured Solutions team and builds on the firm’s track record of capital raising through innovative structured solutions, the fifth such issuance since 2020.

Barings Portfolio Finance acted as the Lead lender for the transaction with Coller Capital and Ares providing the credit enhancement. Citi acted as agent on the transaction. KBRA provided a rating for the debt. Debevoise and Plimpton LLP served as legal counsel for Coller. Proskauer Rose LLP served as legal counsel for Ares. Cadwalader, Wickersham & Taft LLP served as counsel for Barings and Citi.

Remy Kawkabani, Deputy Managing Partner and Head of Capital Formation, Coller Capital, commented: “We are delighted to partner with Barings and Ares on this bespoke structured solution to invest in private market secondaries. Coller brings a 35-year track record of innovative firsts in private markets and we are pleased to lead on the largest-ever structured funding vehicle of its kind for private market secondaries.”

Ian Wiese, Managing Director, Barings Portfolio Finance, commented: “Coller and Barings have a long-standing relationship, and we are pleased to partner to develop an attractive investment grade solution that appeals to institutional investors. As this market continues to innovate, we believe, together with Coller, we will remain at the forefront of creating solutions and look forward to what lies ahead.”

Richard Sehayek, Managing Director, Co-Head of Europe for Ares Alternative Credit, commented: “We are excited to be able to support the Coller team during this dynamic period in global markets. This transaction underscores Ares’ ability to deliver creative, flexible capital solutions that provide important liquidity to market participants, and we look forward to the growing opportunities ahead.”

Mentions
Remy Kawkabani

Deputy Managing Partner and Head of Capital Formation
Press contact
Edelman Smithfield

coller@edelmansmithfield.com+44 (0)7980 684 247

Categories: News

Tags:

Coller Capital Acquires $1.6bn Senior Direct Lending Portfolio in Landmark LP-led Credit Secondaries Transaction

Coller Capital

London, April 2 2025 – Coller Capital, the world’s largest dedicated private market secondaries manager, has acquired a $1.6bn senior direct lending portfolio from American National, a multiline US insurer. The investment marks the largest ever LP-led credit secondaries transaction that is focused on a senior direct lending portfolio.

The transaction will see Coller Capital acquire LP positions in 44 US credit funds that are primarily focused on senior direct lending. The portfolio focuses on first lien and unitranche loans to mid-market companies and, at acquisition, was diversified across over 3,000 loans and nearly 1,500 borrowers, the majority US based.

Coller Capital was approved to buy all funds by the underlying GPs, reflecting the firm’s widely recognised scale, expertise and experience when it comes to structuring and executing LP-led secondaries credit transactions.

Michael Schad, Partner, Head of Coller Credit Secondaries, said: “This investment marks the largest of its kind to date. It is a classic Coller Capital transaction in that it required scale, innovation and specialist expertise to solve a complex challenge. Ultimately, it underlines our pioneering position in the credit secondary space.

“While interest in private credit secondaries continues to grow, the market remains undercapitalized relative to deal volumes. We believe that as more capital becomes available to address this imbalance we will see an increase in transactions of this size.”

Martins Marnauza, Partner at Coller Capital said: “This is a landmark transaction demonstrating the benefits of our global scale and capabilities in the secondary market, as well as the benefits of a seasoned team. The investment highlights our ability to effectively structure and swiftly execute on transactions and helps us continue to provide our investors with exposure to a diversified portfolio of high-quality assets.”

Jefferies LLC acted as adviser to American National, with Debevoise and Plimpton LLP serving as legal counsel. Akin Gump Strauss Hauer & Feld LLP and Simpson Thacher & Bartlett LLP served as legal counsel for Coller Capital.

In 2024, Coller Capital announced the closing of a GP-led transaction to create a continuation vehicle for Abry Advanced Securities Fund III (“ASF III” or the “Fund”). The GP-led transaction represented the largest credit continuation vehicle ever created with $1.6 billion of assets.

Mentions
Black and white formal headshot of Michael Schad.
Michael Schad

Partner, Head of Coller Credit Secondaries
Black and white formal headshot of Martins Marnauza.
Martins Marnauza

Partner, Investment
Press contact
Edelman Smithfield

coller@edelmansmithfield.com+44 (0)7980 684 247

Categories: News

Tags: